Commentary|Videos|October 15, 2025
Navigating Second-Line Treatment Decisions in Lower-Risk MDS
Author(s)Guillermo Garcia-Manero, MD
Fact checked by: Chris Ryan
Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.
Advertisement
Episodes in this series
Advertisement
Related to this article
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Updated NCCN guidelines now recommend rusfertide as a Category 1 option for both low- and high-risk polycythemia vera.
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
3
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
4
Calculating the Real Cost of False Positive Findings in Cancer Screening
5